Valuation: UCB

Market Cap 41.77B 48.19B 39.16B 35.71B 67.19B 4,600B 68.26B 461B 180B 2,302B 181B 177B 7,681B P/E 2026 *
21.9x
P/E 2027 * 18x
Enterprise Value 42.1B 48.56B 39.46B 35.98B 67.7B 4,635B 68.79B 465B 181B 2,320B 182B 178B 7,740B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.13x
Free-Float
61.59%
Yield 2026 *
0.66%
Yield 2027 * 0.69%
1 day-0.86%
1 week-4.07%
Current month-2.29%
1 month-7.69%
3 months-8.39%
6 months-20.53%
Current year-7.25%
1 week 217.35
Extreme 217.35
227
1 month 214.2
Extreme 214.2
251.4
Current year 214.2
Extreme 214.2
289.5
1 year 191.25
Extreme 191.25
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.96
Extreme 54.96
289.5
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-31
Director of Finance/CFO 60 2020-06-30
Chief Tech/Sci/R&D Officer 59 2024-04-30
Director TitleAgeSince
Director/Board Member 55 2011-12-31
Director/Board Member 67 2014-12-31
Director/Board Member 56 2014-04-23
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%-4.07% - - 48.81B
+1.00%+4.39%+43.53%-0.12% 79.68B
+0.97%+3.30%-2.19%+26.99% 50.61B
-1.22%-2.62%+15.13%+167.13% 48.81B
+0.05%+4.12%-49.04%-47.67% 46.91B
+0.85%+2.12%+55.82%-23.03% 30.86B
-0.03%+18.18%+136.71%-37.28% 25.42B
-0.21%+1.81%+40.38%+82.80% 24.48B
-0.32%-0.11%-1.30%+192.44% 21.2B
-3.14%-1.92%+61.19%+161.38% 16.39B
Average -0.30%+3.80%+33.36%+58.07% 38.26B
Weighted average by Cap. -0.02%+3.46%+26.01%+41.73%

Financials

2026 *2027 *
Net sales 8.69B 10.02B 8.14B 7.43B 13.97B 957B 14.2B 95.9B 37.44B 479B 37.63B 36.81B 1,597B 9.69B 11.18B 9.08B 8.28B 15.58B 1,067B 15.83B 107B 41.76B 534B 41.97B 41.06B 1,782B
Net income 1.93B 2.22B 1.8B 1.65B 3.1B 212B 3.15B 21.25B 8.3B 106B 8.34B 8.16B 354B 2.33B 2.69B 2.18B 1.99B 3.74B 256B 3.8B 25.69B 10.03B 128B 10.08B 9.86B 428B
Net Debt 321M 371M 301M 275M 517M 35.37B 525M 3.55B 1.38B 17.7B 1.39B 1.36B 59.06B -1.8B -2.08B -1.69B -1.54B -2.89B -198B -2.94B -19.85B -7.75B -99.13B -7.79B -7.62B -331B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
26-08-13 €219.52 -1.35% 21,384
26-08-12 €222.53 -1.39% 325,448
26-08-11 €225.67 +0.22% 13,305
26-08-10 €225.17 -0.51% 19,288
26-08-07 €226.32 -1.13% 50,964
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
219.10EUR
Average target price
285.26EUR
Spread / Average Target
+30.20%

Quarterly revenue - Rate of surprise